{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:51:58Z","timestamp":1790466718137,"version":"4.1.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Potential but unconfirmed risk factors for coronavirus disease 2019 (COVID-19) in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, ACE (angiotensin-converting enzyme) inhibitors, and Ang II (angiotensin II) receptor blockers. Coronavirus binding to ACE2 (angiotensin-converting enzyme 2), a crucial component of the renin-angiotensin-aldosterone system, underlies much of this concern. Children are uniquely impacted by the coronavirus, but the reasons are unclear. This review will highlight the relationship of COVID-19 with hypertension, use of ACE inhibitors and Ang II receptor blockers, and lifetime risk of cardiovascular disease from the pediatric perspective. We briefly summarize the renin-angiotensin-aldosterone system and comprehensively review the literature pertaining to the ACE 2\/Ang-(1\u20137) pathway in children and the clinical evidence for how ACE inhibitors and Ang II receptor blockers affect this important pathway. Given the importance of the ACE 2\/Ang-(1\u20137) pathway and the potential differences between adults and children, it is crucial that children are included in coronavirus-related research, as this may shed light on potential mechanisms for why children are at decreased risk of severe COVID-19.<\/jats:p>","DOI":"10.1161\/hypertensionaha.120.15291","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T10:00:19Z","timestamp":1588672819000},"page":"16-22","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":119,"title":["ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic"],"prefix":"10.1161","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3204-4142","authenticated-orcid":false,"given":"Andrew M.","family":"South","sequence":"first","affiliation":[{"name":"From the Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine and Brenner Children\u2019s Hospital (A.M.S.)"},{"name":"Department of Surgery-Hypertension and Vascular Research (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC"},{"name":"Division of Public Health Sciences, Department of Epidemiology and Prevention (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC"},{"name":"Cardiovascular Sciences Center (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy M.","family":"Brady","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD (T.M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Flynn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine and Division of Nephrology, Seattle Children\u2019s Hospital (J.T.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0279-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000618"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5394"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6913e2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0275-x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461"},{"key":"e_1_3_3_12_2","article-title":"Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension [preprint].","author":"Yang G","year":"2020","unstructured":"Yang, G, Tan, Z, Zhou, L, Yang, M, Peng, L, Liu, J, Cai, J, Yang, R, Han, J, Huang, Y, et al. Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension [preprint]. medRxiv. 2020. doi 10.1101\/2020.03.31.20038935","journal-title":"medRxiv"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.07.20056788"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6914e4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005073"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.1346"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.3310"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1939-1"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-0877"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12879"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-2002"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20171550"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000251865.35728.2f"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.02.001"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb14014.x"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2012.161"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2019.01.004"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.03624"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001801"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.03.018"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.03.055"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1203\/01.pdr.0000246100.14061.bc"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3665-9"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2016_84"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09797-y"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.11.022"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000355618"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00618.2015"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-14-117"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2009.01.014"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316659618"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00201"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11397"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00217.2020"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep19840"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00009.2008"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-019-0529-4"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1643-8"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02153.x"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m810"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000124667.34652.1a"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.02.088"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu086"},{"key":"e_1_3_3_59_2","first-page":"625","article-title":"[Effects of angiotensin converting enzyme inhibitor on the expression of angiotensin converting enzyme 2 in atrium of patients with atrial fibrillation].","volume":"35","author":"Hu XS","year":"2007","unstructured":"Hu, XS, Xie, XD, Wang, XX, Zeng, CL, Ni, YM, Yu, GW, Chen, JZ. [Effects of angiotensin converting enzyme inhibitor on the expression of angiotensin converting enzyme 2 in atrium of patients with atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:625\u2013628.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1670"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000187500.24964.7A"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13462"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-015-0044-3"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03712"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.104350"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03530320"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.120.15082"},{"key":"e_1_3_3_69_2","unstructured":"Sparks MA Hiremath S South AM Welling PA et al. The Coronavirus Conundrum: ACE2 and Hypertension Edition. http:\/\/www.nephjc.com\/news\/covidace2. Accessed April 10 2020."},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa097"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.120.15291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:43:37Z","timestamp":1715597017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.120.15291"}},"subtitle":["The Pediatric Perspective"],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.120.15291"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.120.15291","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2020-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}